Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma

Garcia, Alejandro J.; Recondo, Gonzálo; Greco, Martín; Vega, Máximo de la; Perazzo, Florencia; Avagnina, Alejandra; Denninghoff, Valeria

doi:10.1016/j.heliyon.2020.e04117

Cited by 9 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-surgical ctDNA-positive patients and PD-L1 status. Solid subtype (high grade) LUAD histology, proliferation rate, and poor outcomes have previously been associated with raised PD-L1 levels in LUAD 21,22 . Given that pre-surgical ctDNA detection in clinical stage I LUAD associates with similar features, we sought to determine whether pre-surgical ctDNA-positive patients had a distinct PD-L1 distribution relative to pre-surgical ctDNA-negative patients.…”

Section: Resultsmentioning

confidence: 99%

Tumor-naïve pre-surgical ctDNA detection is prognostic in clinical stage I lung adenocarcinoma

Hong,

Hwang,

Dasgupta

et al. 2024

Preprint

View full text Add to dashboard Cite

We assessed pre-surgical diagnostic circulating tumor DNA (ctDNA) status in 895 patients with EGFR/ALK-wild-type, clinical stage I–II non-small-cell lung cancer using a tumor-naïve methylation-based cell-free DNA assay. Pre-surgical ctDNA detection was observed in 55/414 (13%) patients with clinical stage I lung adenocarcinoma (LUAD) and was associated with poor recurrence-free survival (RFS) (2-year RFS 69% versus 91%; log-rank P < 0.001), approaching that of clinical stage II LUAD. Pre-surgical ctDNA detection was not prognostic in patients with clinical stage II LUAD or non-LUAD. Within LUAD, tumor volume interacted with positron emission tomography avidity to predict pre-surgical ctDNA detection, and pre-surgical ctDNA detection correlated with high-grade pathological features, programmed death ligand-1 (PD-L1) positivity, and pathological upstaging. Our findings support pre-surgical ctDNA positivity as an adverse prognostic feature specifically in clinical stage I LUAD. This validated observation using a tumor-naïve assay will enable perioperative trial advances targeted toward patients with high-risk disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Tumor-naïve pre-surgical ctDNA detection is prognostic in clinical stage I lung adenocarcinoma

Hong,

Hwang,

Dasgupta

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Non-metastatic lesions are HGSC primary ovarian lesions that are absent from the omentum or other sites. We rated PD-L1 expressions 1% as negative, >1% to 5% as low, >5% to 50% as moderate, and >50% as high using the PD-L1 clone 28-8 score method [ 25 ].…”

Section: Methodsmentioning

confidence: 99%

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

Masadah,

Ikram,

Riadi

et al. 2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Introduction: Ovarian cancer is a primary cause of cancer-related death in women. At the time of diagnosis, the majority of ovarian malignancies had metastasized. It is believed that cancer stem cells (CSCs) and immune evasion play a crucial role in the metastatic process. The objective of this study was to describe the expression profiles of cluster of differentiation (CD)133, CD47 , and programmed death ligand 1 ( PD-L1 ) in high-grade serous ovarian cancer (HGSC) as commonly utilized markers for CSCs and immune evasion. Material and methods: Using an immunohistochemical procedure, 51 HGSC tissue samples were stained with anti- CD133 , anti- CD47 , and anti- PDL1 antibodies. The samples contained 31 HGSC with metastases and 20 HGSC absent metastases. The expression of CD133, CD47 , and PD-L1 was compared between groups. Results: Strong expression of CD133 and CD47 was seen in 52% and 66% of tissue samples, respectively. Twenty of the thirty-one patients with metastases had a significant level of CD133 expression, with a p-value of 0.039. CD47 expression was increased in 26 of 31 samples with metastatic disease. A 62.7 percent of samples were negative for PD-L1 expression, significantly inversely correlated with HGSC metastatic disease (p=0.023). Although there was no significant association between CD133, CD47, or PD-L1 expression and age, Tumor Infiltrating Lymphocytes demonstrated a significantly varied relationship. Conclusion: Our findings suggested that expression of CD133, CD47 , and PD-L1 may have dynamically increased as the primary lesion progressed to the metastatic lesion, implying that these proteins may be involved in the progression of high-grade serous ovarian cancer from the primary to the metastatic stage.

show abstract

“…Membrane staining in epithelial cells was considered positive if a brown color of strong or moderate intensity was observed in basolateral or all cell membrane, and the percentage of stained tumor cells in total tumor cells (or tumor proportion score, TPS) in the chosen area was estimated [ 20 ]. Based on cut-offs established in previous studies, results were stratified in five TPS groups according to the percentage of positive tumor cells: 0 (0%), 1 (≥ 1% and < 5%), 2 (≥ 5% and < 10%), 3 (≥ 10% and < 20%), 4 (≥ 20% and < 50%), and 5 (≥ 50%) [ 21 ].…”

Section: Methodsmentioning

confidence: 99%

Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients

et al. 2023

View full text Add to dashboard Cite

Programmed death-ligand 1 (PD-L1) is overexpressed in cervical carcinoma, hindering tumor destruction. The aim of this study was to assess PD-L1 expression by immunohistochemistry in cervical squamous cell carcinoma (SCC) and squamous intraepithelial lesions (SILs) from human immunodeficiency virus–positive (HIV+) and human immunodeficiency virus-negative (HIV-) patients. A total of 166 SCC and SIL samples of HIV+ and HIV- patients were included and analyzed for PD-L1 expression through tumor proportion score (TPS), and results were stratified in five TPS groups using SP263 antibody and, combined positive score (CPS) using 22C3 antibody. In cohort 1 (SP263 clone), all HIV+ patients were negative for intraepithelial lesion or malignancy (NILM), and low-grade squamous intraepithelial lesions (LSILs) scored < 1; and 87.5% of high-grade squamous intraepithelial lesions (HSILs) adjacent to SCC, 19% of HSILs non-adjacent to SCC, and 69% of SCCs scored ≥ 1 (15.4% scored 5). In HIV- patients, all NILM, LSILs, HSILs adjacent to SCC, and two HSILs non-adjacent to SCC scored < 1. SCC: 88.2% scored ≥ 1 and 5.9% scored 5. In cohort 2 (SP263 and 22C3 clones), 16.7% of HIV+ patients with SCC were positive with both clones, CPS ≥ 1 (22C3) or score 5 (≥ 50%) (SP263), showing no significant differences in positivity between both clones. These results indicate that a relatively low percentage of SCCs (16.7%; both in HIV+ and in HIV- patients) express PD-L1 (TPS ≥ 50% and CPS > 1), which may be due to some samples being archival material, sample characteristics, or use of different methodologies, highlighting the need for standardization of PD-L1 assessment in SCC of the cervix. The fact that PD-L1 is overexpressed in SILs of HIV+ patients suggests potential additional applications for immunotherapy in this disease.

show abstract

Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma

Cited by 9 publications

References 27 publications

Tumor-naïve pre-surgical ctDNA detection is prognostic in clinical stage I lung adenocarcinoma

Tumor-naïve pre-surgical ctDNA detection is prognostic in clinical stage I lung adenocarcinoma

CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study

Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients

Contact Info

Product

Resources

About